

PHARMACEUTICAL 2023

Janux Therapeutics Inc. Rank 53 of 446









RealRate



The relative strengths and weaknesses of Janux Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Janux Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Janux Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 240%, being 196% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	332,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,507
Liabilities, Non-Current	26,763
Other Assets	24,485
Other Compr. Net Income	-1,265
Other Expenses	0
Other Liabilities	0
Other Net Income	4,032
Other Revenues	8,612
Property and Equipment	7,086
Research and Development	53,441
Selling, General and Administrative Expense	22,262

Output Variable	Value in 1000 USD
Assets	364,010
Liabilities	43,270
Expenses	75,703
Revenues	8,612
Stockholders Equity	320,740
Net Income	-63,059
Comprehensive Net Income	-63,692
Economic Capital Ratio	240%

